Lunit AI Solution for Breast Cancer Detection Wins Commercial Approval in Taiwan
Lunit's AI solution for mammography received a class 2 medical device license from the Taiwan Food and Drug Administration Lunit's latest commercial approval to accelerate expansion in the Taiwanese market SEOUL, South Korea, Aug. 25, 2022 /PRNewswire/ -- Lunit (KRX: 328130.KQ), a leading medical AI provider, today announced that it received...
Doctors at Manipal Hospitals, Dwarka give new lease of life to a 30-day-old newborn suffering from brain tumor
NEW DELHI and KHARTOUM, Sudan, Aug. 25, 2022 /PRNewswire/ -- Doctors at Manipal Hospitals, Delhi successfully saved the life of a 30-day-old newborn baby with a brain tumor. The baby was presented at the hospital in an emergency with a complaint of seizures and unconsciousness. Upon further diagnosis, a CT scan found a...
Innovent Announced 2022 Interim Results and Business Updates
Leading the Way in Developing a More Sustainable Business Model for Innovative Biopharmaceutical Companies Commercial Model and Platform Upgraded to Stage 2.0 A Robust Pipeline of 34 Valuable Assets Supporting Continuously Growth Momentum ROCKVILLE, Md. and SUZHOU, China, Aug. 25, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that...
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe
Second region now open for enrolment for rare, rapidly progressive, neurodegenerative disease MELBOURNE, Australia and SAN FRANCISCO, Aug. 25, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company's Phase 2 clinical trial of...
Tigermed Reports 2022 Interim Result with Strong Financial Growth
HANGZHOU, China, Aug. 25, 2022 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its interim results for the first half of 2022, ended June 30, 2022 (the "Reporting Period"). This press release is for...
CStone Pharmaceuticals Reports 2022 Interim Results and Business Updates
SUZHOU, China, Aug. 25, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today reported 2022 interim financial results and recent business highlights, and leadership transition. In the first of 2022, CStone continued to achieve breakthroughs with eye-catching performance. So far this year, we've...
111, Inc. Announces Second Quarter 2022 Unaudited Financial Results
SHANGHAI, Aug. 25, 2022 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced its unaudited financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Key Results Net revenues were RMB3.04 billion (US$453.4...
Alpha Biopharma Announces Completion of its EVEREST Phase II/III Clinical Study of Zorifertinib in Non-Small Cell Lung Cancer Patients with Central Nervous System Metastases
Zorifertinib is a next generation EGFR-TKI with full Blood Brain Barrier penetration targeting EGFRm+ NSCLC patients with CNS metastases Top-line data from the study are expected around the end of 2022 SHANGHAI, Aug. 25, 2022 /PRNewswire/ -- Alpha Biopharma, a developer of innovative drugs, announces the completion of last patient last visit (LPLV) in its international, multicenter...
DFI Unveils ATX Motherboard ICX610-C621A Facilitating the Integration of AI Computing
TAIPEI, Aug. 25, 2022 /PRNewswire/ -- DFI, the global leading provider of high-performance computing technology across multiple embedded industries, unveils a server-grade ATX motherboard, designed for Intel® Ice Lake platform, powered by the 3rd Generation Intel® Xeon® Scalable processors, and equipped with ultra-high speed computing that can support up to 205W. ICX610-C621A also comes with built-in Intel® Speed Select Technology (Intel®...
Asieris Pharmaceuticals (688176.SH) Issued 2022 Semi-Annual Report: Accelerated Global Clinical Development and Progressive Implementation of Its Integrated Diagnosis-Treatment Commercialization Strategy
SHANGHAI, Aug. 25, 2022 /PRNewswire/ -- Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, issued its 2022 semi-annual report today. As disclosed in the report, the company has made significant progress in multiple global and China clinical trials for its core investigational products...
